Difference between revisions of "Thyroid cancer"
Jump to navigation
Jump to search
(cabozantinib) |
m |
||
| Line 8: | Line 8: | ||
==Cabozantinib (Cometriq)== | ==Cabozantinib (Cometriq)== | ||
===Regimen=== | ===Regimen=== | ||
| − | *[[Cabozantinib (Cometriq)]] 140 mg PO | + | Level of Evidence: |
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Non-randomized</span> | ||
| + | |||
| + | *[[Cabozantinib (Cometriq)]] 140 mg PO once per day, at least 2 hours before or 1 hour after meals | ||
===References=== | ===References=== | ||
| + | # Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. [http://jco.ascopubs.org/content/29/19/2660.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21606412 PubMed] | ||
*[http://cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf Cabozantinib (Cometriq) package insert] | *[http://cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf Cabozantinib (Cometriq) package insert] | ||
| + | |||
| + | ==Placebo== | ||
| + | |||
| + | ===Regimen=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |||
| + | ''No treatment. Included for reference purposes only.'' | ||
| + | |||
| + | ===References=== | ||
| + | # Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. [http://jco.ascopubs.org/content/30/2/134.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22025146 PubMed] | ||
==Sorafenib (Nexavar)== | ==Sorafenib (Nexavar)== | ||
===Regimen=== | ===Regimen=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
*[[Sorafenib (Nexavar)]] 400 mg PO BID | *[[Sorafenib (Nexavar)]] 400 mg PO BID | ||
| Line 22: | Line 55: | ||
==Sunitinib (Sutent)== | ==Sunitinib (Sutent)== | ||
===Regimen=== | ===Regimen=== | ||
| − | *[[Sunitinib (Sutent)]] 37.5 mg PO | + | Level of Evidence: |
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
| + | *[[Sunitinib (Sutent)]] 37.5 mg PO once per day | ||
===References=== | ===References=== | ||
| Line 29: | Line 70: | ||
==Vandetanib (Caprelsa)== | ==Vandetanib (Caprelsa)== | ||
===Regimen #1, Wells, et al. 2010 & Wells, et al. 2012=== | ===Regimen #1, Wells, et al. 2010 & Wells, et al. 2012=== | ||
| − | *[[Vandetanib (Caprelsa)]] 300 mg PO | + | Level of Evidence: |
| + | <span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |||
| + | *[[Vandetanib (Caprelsa)]] 300 mg PO once per day | ||
===Regimen #2, Robinson, et al. 2010=== | ===Regimen #2, Robinson, et al. 2010=== | ||
| − | *[[Vandetanib (Caprelsa)]] 300 mg PO | + | Level of Evidence: |
| + | <span | ||
| + | style="background:#ff0000; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II, <20 patients reported</span> | ||
| + | |||
| + | *[[Vandetanib (Caprelsa)]] 300 mg PO once per day | ||
===References=== | ===References=== | ||
| Line 42: | Line 99: | ||
==Axitinib (Inlyta)== | ==Axitinib (Inlyta)== | ||
===Regimen=== | ===Regimen=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
*[[Axitinib (Inlyta)]] 5 mg PO BID | *[[Axitinib (Inlyta)]] 5 mg PO BID | ||
| Line 49: | Line 114: | ||
==Sorafenib (Nexavar)== | ==Sorafenib (Nexavar)== | ||
===Regimen=== | ===Regimen=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
*[[Sorafenib (Nexavar)]] 400 mg PO BID | *[[Sorafenib (Nexavar)]] 400 mg PO BID | ||
| Line 56: | Line 129: | ||
==Sunitinib (Sutent)== | ==Sunitinib (Sutent)== | ||
===Regimen=== | ===Regimen=== | ||
| − | *[[Sunitinib (Sutent)]] 37.5 mg PO | + | Level of Evidence: |
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
| + | *[[Sunitinib (Sutent)]] 37.5 mg PO once per day | ||
===References=== | ===References=== | ||
# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [http://clincancerres.aacrjournals.org/content/16/21/5260.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20847059 PubMed] | # Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [http://clincancerres.aacrjournals.org/content/16/21/5260.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20847059 PubMed] | ||
Revision as of 01:40, 15 July 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Medullary thyroid cancer
Cabozantinib (Cometriq)
Regimen
Level of Evidence: Non-randomized
- Cabozantinib (Cometriq) 140 mg PO once per day, at least 2 hours before or 1 hour after meals
References
- Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. link to original article contains verified protocol PubMed
Placebo
Regimen
Level of Evidence: Phase III
No treatment. Included for reference purposes only.
References
- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains verified protocol PubMed
Sorafenib (Nexavar)
Regimen
Level of Evidence: Phase II
- Sorafenib (Nexavar) 400 mg PO BID
References
- Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10;28(14):2323-30. Epub 2010 Apr 5. link to original article contains verified protocol PubMed
Sunitinib (Sutent)
Regimen
Level of Evidence: Phase II
- Sunitinib (Sutent) 37.5 mg PO once per day
References
- Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains verified protocol PubMed
Vandetanib (Caprelsa)
Regimen #1, Wells, et al. 2010 & Wells, et al. 2012
Level of Evidence: Phase III
- Vandetanib (Caprelsa) 300 mg PO once per day
Regimen #2, Robinson, et al. 2010
Level of Evidence: Phase II, <20 patients reported
- Vandetanib (Caprelsa) 300 mg PO once per day
References
- Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10;28(5):767-72. Epub 2010 Jan 11. link to original article contains verified protocol PubMed
- Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. Epub 2010 Apr 6. link to original article contains verified protocol PubMed content property of HemOnc.org
- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains verified protocol PubMed
Various histologies
Axitinib (Inlyta)
Regimen
Level of Evidence: Phase II
- Axitinib (Inlyta) 5 mg PO BID
References
- Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article contains verified protocol PubMed
Sorafenib (Nexavar)
Regimen
Level of Evidence: Phase II
- Sorafenib (Nexavar) 400 mg PO BID
References
- Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article contains verified protocol PubMed
Sunitinib (Sutent)
Regimen
Level of Evidence: Phase II
- Sunitinib (Sutent) 37.5 mg PO once per day
References
- Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains verified protocol PubMed